|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
|
BACK TO LIST |
European Patient Summary
|
|
|
|||||||||||||||||||
Problem list
| Condition | Onset Date | Status |
|---|---|---|
| Alzheimer's disease | 2025-05-21 | active |
| Chronic sinusitis | 2022-11-06 | active |
| Acute non-ST segment elevation myocardial infarction | 2016-09-12 | active |
| Ischemic heart disease | 2012-03-07 | active |
| Recurrent rectal polyp | 2005-12-19 | active |
| Polyp of colon | 2004-07-06 | active |
| Proteinuria due to type 2 diabetes mellitus | 2002-09-25 | active |
| Osteoarthritis of knee | 1998-11-06 | active |
| Microalbuminuria due to type 2 diabetes mellitus | 1989-05-10 | active |
| Metabolic syndrome X | 1987-09-30 | active |
| Essential hypertension | 1986-09-24 | active |
| Disorder of kidney due to diabetes mellitus | 1986-09-24 | active |
| Anemia | 1974-09-11 | active |
| Prediabetes | 1971-09-08 | active |
Medication list
| Medication | Since | Form | Dosage | Reason |
|---|---|---|---|---|
| insulin isophane human 70 UNT/ML / insulin regular human 30 UNT/ML Injectable Suspension [Humulin] | 2025-05-20 | Inject 10 units (0.1 mL) subcutaneously before breakfast and before dinner | Prediabetes | |
| Acetaminophen 325 MG Oral Tablet [Tylenol] | 2025-05-20 | 1 tablet (325 mg) by mouth every 4 to 6 hours as needed | ||
| Amlodipine (as amlodipine besylate) 2.5 mg oral tablet | 2025-05-20 | Oral tablet | 1 tablet (2.5 mg) by mouth once daily | Essential hypertension (disorder) |
| Galantamine (as galantamine hydrobromide) 4 mg oral tablet | 2025-05-20 | Oral tablet | 1 tablet (4 mg) once daily | Alzheimer's disease (disorder) |
| Hydrochlorothiazide 25 mg oral tablet | 2025-05-20 | Oral tablet | 1 tablet (25 mg) by mouth once daily | Essential hypertension (disorder) |
| Lisinopril 10 mg oral tablet | 2025-05-20 | Oral tablet | 1 tablet (10 mg) by mouth once daily | Essential hypertension (disorder) |
| Tramadol hydrochloride 50 mg oral tablet | 2025-05-20 | Oral tablet | 1 tablet (50 mg) every 4 to 6 hours as needed | |
| Acetaminophen 325 MG / Oxycodone Hydrochloride 10 MG Oral Tablet [Percocet] | 2025-05-20 | 1 tablet (325 mg/10 mg) by mouth every 6 hours as needed for pain | ||
| 24 HR tacrolimus 5 MG Extended Release Oral Capsule | 2025-05-20 | 5 mg by mouth once daily | History of renal transplant (situation) | |
| Clopidogrel (as clopidogrel bisulfate) 75 mg oral tablet | 2012-03-13 | Oral tablet | 1 tablet (75 mg) once daily | |
| Simvastatin 20 mg oral tablet | 2012-03-13 | Oral tablet | 1 tablet (20 mg) by mouth once daily | |
| Nitroglycerin 400 microgram/actuation sublingual spray | 2012-03-13 | Sublingual spray | 400 micrograms per spray, 1 spray under the tongue as needed for chest pain, may repeat every 5 minutes as needed, up to 3 sprays in 15 minutes | |
| Metoprolol tartrate (as metoprolol succinate) 100 mg prolonged-release oral tablet | 2012-03-13 | Prolonged-release oral tablet | 1 tablet (100 mg) once daily | |
| Naproxen sodium 220 MG Oral Tablet | 1998-11-05 | 1 tablet (220 mg) every 12 hours as needed | Osteoarthritis of knee |
Allergies and Intolerances
| No known allergies or intolerances |
Procedure History list
| Procedure | Date | Reason |
|---|---|---|
| Patient discharge | 2024-08-17 | - |
| Hospice care | 2024-08-16 | - |
| Notifications | 2024-07-10 | - |
| Certification procedure | 2024-07-10 | - |
| Initial patient assessment | 2024-07-10 | - |
| Development of individualized plan of care | 2024-07-10 | - |
| Depression screening | 2023-08-09 | - |
| Assessment of health and social care needs | 2023-08-09 | - |
| Screening for drug abuse | 2023-08-09 | - |
| Assessment of substance use | 2023-08-09 | - |
| 2023-08-09 | - | |
| Medication reconciliation | 2022-11-16 | - |
| Assessment using AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) | 2022-11-16 | - |
| Screening for domestic abuse | 2022-11-16 | - |
| Assessment of anxiety | 2022-09-21 | - |
| Assessment using Morse Fall Scale | 2022-09-21 | - |
| Laboratory test | 2016-09-12 | - |
| Electrocardiographic procedure | 2016-09-12 | - |
| Diagnostic assessment | 2016-09-12 | - |
| Risk assessment | 2016-09-12 | Acute non-ST segment elevation myocardial infarction (disorder) |
| Oxygen administration by mask | 2016-09-12 | - |
| Plain X-ray of chest | 2016-09-12 | - |
| Assessment of cardiac status using monitoring device | 2016-09-12 | - |
Immunizations list
| Vaccine | Date |
|---|---|
| Influenza virus antigen only vaccine product | 2025-05-20 |
| SARS-CoV-2 mRNA vaccine | 2021-05-04 |
| Clostridium tetani toxoid antigen adsorbed only vaccine product | 2021-04-27 |
| Streptococcus pneumoniae Danish serotype 1 | 2016-03-29 |
Care Plan
| Immunization Recommendation | Due Date | Reason |
|---|---|---|
| Vaccine product containing only Influenza virus antigen (medicinal product) | 2025-10-01 | Annual seasonal influenza vaccination |
History of Past Illness
| Condition | Period | Status |
|---|---|---|
| Viral sinusitis | 2023-08-23 – 2023-08-30 | inactive |
| Sinusitis | 2022-10-05 – 2023-01-01 | inactive |
| Acute bronchitis | 2019-07-27 – 2019-08-04 | inactive |
| Acute bronchitis | 2016-11-30 – 2016-12-08 | inactive |
| Myocardial infarction | 2016-09-12 – 2016-09-17 | inactive |
Vital Signs
| Vital Signs | 2025-05-20 | 2024-05-14 |
|---|---|---|
| Body Height | 177.6 cm | 177.6 cm |
| Pain severity - 0-10 verbal numeric rating [Score] - Reported | 4 {score} | 2 {score} |
| Body Weight | 95.9 kg | 95.9 kg |
| Body mass index (BMI) [Ratio] | 30.4 kg/m2 | 30.4 kg/m2 |
| Diastolic Blood Pressure | 69 mm[Hg] | 66 mm[Hg] |
| Systolic Blood Pressure | 82 mm[Hg] | 88 mm[Hg] |
| Heart rate | 77 /min | 83 /min |
| Respiratory rate | 15 /min | 16 /min |